Genmab — December 2017
-
Highlights from ASH 2017: Research Update on AL amyloidosis http://www.arci.org/blog-1/2017/12/14/highlights-from-ash-2017-research-update
-
video - Major breakthroughs in AL amyloidosis treatment from ASH 2017 - https://www.vjhemonc.com/video/fpeohrztdaq-major-breakthroughs-in-al-amyloidosis-treatment-from-ash-2017/
-
Et lille sidespring. Hermed min analyse fra i dag på Nuevolution lægemiddeludviklingsmaskine. http://www.proinvestor.com/aktieanalyser/255/
-
Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. - https://www.ncbi.nlm.nih.gov/pubmed/29260507
-
-
-
Assessing the BCMA scene
Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric...
BioCentury (www.biocentury.com)
-
https://endpts.com/nanjing-legend-wows-asco-researchers-with-early-data-on-a-bcma-targeted-car-t-contender/
Legende data blev præsenteret på ASCO 2017, men blev betragtet med skepsis da de er et kinesisk selskab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind